Neuronetics

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Neuronetics sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 3 currently recruiting 6 completed later-stage tilt top decile by trial count

Neuronetics: 11 sponsored US clinical trials, 3 recruiting.

Neuronetics sponsors 11 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Anxiety Depression, with 2 trials.

Top-decile sponsor footprint

Neuronetics ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Where Neuronetics enrollment is open (later-stage tilt)

3 recruiting of 11 indexed (27% open); 6 completed (55%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Anxiety Depression (2 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Neuronetics: open-pipeline peers nationwide

Peers matched on 11 registered trials and 27% open enrollment, not the therapeutic-area sidebar.

Neuronetics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30% Total trials Recruiting share NeuroneticsAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeConnecticut Children's Medical CenterCriteriumMinneapolis Heart Institute FoundationNerviano Medical Sciences
Neuronetics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Neuronetics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 27% open enrollment (± trial volume)

What to do with this Neuronetics page

11 registered trials is a research-attention snapshot, not an endorsement of Neuronetics or any single study.

  • 3 of Neuronetics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Anxiety Depression is the condition Neuronetics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Anxiety Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Neuronetics pipeline card: 11 registered trials from official public datasets.Report a data error.